INTS9

Across TCGA pan-cancer cohorts, INTS9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated INTS9 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher INTS9 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated INTS9 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where INTS9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.776	0.970	.009	20	view →
PDAC	DFS	Tertile	III,IV	0.352	0.828	.031	6	view →
LUAD	DFS	Median	II,III,IV	1.000	0.819	.034	4	view →
CCRCC	OS	Tertile	All	0.934	0.780	.046	2	view →
LSCC	DFS	Tertile	All	0.799	0.573	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

INTS9–HNSC (OS)

Open the HNSC breakdown →